Trial Profile
Phase 2 Study of Canfosfamide HCl for Injection (Telcyta, TLK286) in Refractory or Relapsed Mantle Cell Lymphoma (MCL), Diffuse Large B Cell Lymphoma (DLBCL) and Multiple Myeloma (MM).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Canfosfamide (Primary)
- Indications Diffuse large B cell lymphoma; Mantle-cell lymphoma; Multiple myeloma
- Focus Therapeutic Use
- Sponsors Telik
- 01 Sep 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 Apr 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Apr 2012 New source identified and integrated (Memorial Sloan-Kettering Cancer Center: 12-019).